Scientific deep-dive

Does Wegovy Cause Hair Loss? What the FDA Label Says (2026)

Wegovy's label: hair loss in 3.3% on 2.4 mg vs 1% on placebo (4% of women, 0.9% of men), 5.8% on 7.2 mg. When shedding starts and what helps.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
11 min read·11 citations

Yes — Wegovy can cause hair loss, and its own prescribing information says so: in the pooled 68-week adult weight-loss trials, 3.3% of people on Wegovy 2.4 mg reported hair loss versus 1% on placebo, and the label states these reactions “were associated with weight reduction”[1]. Almost all of it was in women (4% of women vs 0.9% of men), the rate climbed to 5.8% on the newer 7.2 mg dose[1], and the pattern fits telogen effluvium — a temporary, nonscarring shed that follows rapid weight loss — rather than damage to the follicle[8][10]. Below: exactly what the Wegovy label reports, how the STEP trials' weight loss lines up with that number, when shedding tends to show up relative to the 16-week dose climb, and what to do about it.

Short version for Wegovy users: hair loss is a listed, common Wegovy side effect (about 1 in 30 adults at 2.4 mg, about 1 in 12 women at 7.2 mg). It comes up so often that we answer the recurring semaglutide side-effect questions separately, with the trial numbers behind each. It tracks how much weight comes off, it is diffuse rather than patchy, and in reviews of GLP-1 users it most often looks like telogen effluvium, which usually improves within a few months once weight levels off[10]. Patchy bald spots, scarring, or a receding pattern are different problems and need a clinician.

What the Wegovy label actually reports

Wegovy is semaglutide approved for chronic weight management (plus cardiovascular risk reduction and, as an injection, MASH). Its label lists hair loss among the most common adverse reactions in Section 6.1 and gives a dedicated paragraph with the sex breakdown. The adult figure comes from a pool of the label's Studies 2, 3 and 4 — registered as NCT03548935, NCT03552757 and NCT03611582, which are STEP 1, STEP 2 and STEP 3 in the published literature[2][3][4]. The wording, verbatim:

“Hair loss adverse reactions in WEGOVY injection-treated patients were associated with weight reduction. In a pool of studies 2, 3, and 4, hair loss was reported in 3.3% of patients treated with WEGOVY 2.4 mg (4% female, 0.9% male) and in 1% of patients treated with placebo (2% female, 0 male). In a pediatric trial, hair loss was reported in 4% of patients treated with 2.4 mg of WEGOVY and no placebo-treated patients.”
— WEGOVY prescribing information, Section 6.1 (DailyMed)
Hair loss in Wegovy trials, as reported in the Wegovy prescribing information (Section 6.1)
Trials (label)WegovyPlaceboWomen / men on Wegovy
Adults, 2.4 mg — Studies 2–4 (STEP 1–3), 68 weeks3.3%1% (2% of women, 0 men)4% / 0.9%
Adults, 7.2 mg trials (STEP UP program), 72 weeks5.8% on 7.2 mg; 3.3% on 2.4 mg1.0% (1.5% of women, 0 men)7.2 mg: 8.4% / 0.2%; 2.4 mg: 5.4% / 0
Adolescents 12+, 2.4 mg (STEP TEENS), 68 weeks4%0Not broken out
Adults, 25 mg tablet (Study 7), 64 weeksNo separate hair-loss figure—Label says the common reactions were similar in type and frequency to those in the injection trials

Two details in that section are easy to miss. First, in the 7.2 mg trials hair loss was the reason for one permanent discontinuation, one temporary interruption and five dose reductions in the 7.2 mg group, versus none of these in the 2.4 mg or placebo groups[1] — so at the top dose it occasionally changed treatment, but rarely. Second, the adolescent rate (4% vs 0) comes from the 201-participant STEP TEENS trial, in which BMI fell 16.1% on semaglutide versus a 0.6% rise on placebo over 68 weeks[7][1].

Magnitude comparison

Hair loss reported in the Wegovy 7.2 mg trials, by dose and sex (Wegovy prescribing information, Section 6.1). Nearly every case was in women; the rate rises with dose.[1]

  • Placebo — women1.5 %
  • Wegovy 2.4 mg — women5.4 %
  • Wegovy 7.2 mg — women8.4 %
  • Placebo — men0.0 %
  • Wegovy 2.4 mg — men0.0 %
  • Wegovy 7.2 mg — men0.2 %
Hair loss reported in the Wegovy 7.2 mg trials, by dose and sex (Wegovy prescribing information, Section 6.1). Nearly every case was in women; the rate rises with dose.

Why women see it far more often on Wegovy

The sex gap is the most striking thing in the Wegovy data. In the 2.4 mg pool, women on Wegovy reported hair loss at twice the female placebo rate (4% vs 2%), while men barely registered (0.9% vs none). In the 7.2 mg trials the split widened: 8.4% of women versus 0.2% of men[1]. Because the STEP trials enrolled mostly women — 74% in STEP 1 and 81% in STEP 3, per the label's trial descriptions — the headline 3.3% blends a higher female rate with a near-zero male one. A woman deciding about Wegovy should read the 4% (2.4 mg) or 8.4% (7.2 mg) figure as her number.

The label does not explain the gap, and neither should we overstate it. What outside evidence shows is consistent: a systematic review of GLP-1 drugs and hair loss found women disproportionately affected[10], and a Korean dermatology clinic's review of 140 people with weight-loss telogen effluvium (110 of them women) concluded that women and older adults are especially vulnerable even when they lose no more weight than men[9].

How much weight Wegovy removes — and why the hair number follows it

The label ties Wegovy's hair loss to weight reduction, so the size of that reduction matters. At 68 weeks, average weight change on Wegovy 2.4 mg versus placebo was[1]:

  • STEP 1 (obesity or overweight with a comorbidity): −14.9% vs −2.4%[2].
  • STEP 2 (adults with type 2 diabetes): −9.6% vs −3.4% — the label notes Wegovy produced less weight reduction in people with type 2 diabetes[3][1].
  • STEP 3 (with intensive behavioral therapy and an initial low-calorie diet): −16% vs −5.7%[4].
  • STEP UP (72 weeks): −18.7% on 7.2 mg vs −15.6% on 2.4 mg and −3.9% on placebo in the published trial[6].

Line those up with the hair figures and the direction is the same: more weight off, more shedding reported — 3.3% at 2.4 mg, 5.8% at 7.2 mg. A useful benchmark from outside the drug world: in the Korean weight-loss telogen effluvium series, patients had lost an average of about 15% of body weight, at roughly 3.5 kg a month, before the shed brought them in[9]. That is almost exactly the average loss STEP 1 produced on Wegovy 2.4 mg, which helps explain why a 2.4 mg weight-management dose sits in a different hair-loss bracket than lower diabetes doses of the same molecule. The GLP-1 systematic review made the same observation from the other side: semaglutide-associated hair loss looked dose-dependent, with doses under 2 mg weekly rarely implicated[10]. (For what Ozempic's own label says, see Ozempic and hair loss; for the molecule across every product, see semaglutide and hair loss.)

Timing: the 16-week dose climb and when shedding shows up

Wegovy injection starts low and steps up every four weeks: 0.25 mg in weeks 1–4, 0.5 mg in weeks 5–8, 1 mg in weeks 9–12, 1.7 mg in weeks 13–16, then a maintenance dose from week 17 — 2.4 mg recommended, 1.7 mg allowed. People who have tolerated 2.4 mg for at least four weeks and need more weight loss can go up to 7.2 mg[1].

Telogen-type shedding lags its trigger. A 2026 systematic review of GLP-1 hair loss puts the expected delay at roughly 2–3 months after starting treatment, and 1.5–3 months after starting or increasing a dose if the shed is weight-loss telogen effluvium[10]. On the Wegovy schedule, that window lands in the back half of the titration and the first weeks at maintenance — months 2 to 4 of treatment. The same logic means a later step from 2.4 mg to 7.2 mg can start a fresh window a couple of months afterward.

Recovery tends to follow the weight curve, not the calendar. The same review reports that telogen effluvium typically improves within 3–6 months once weight stabilizes[10]. On Wegovy, weight keeps changing long after the 16-week titration — STEP 1 measured its main result at week 68[2] — so the shed may not settle until your weight does.

Should you stop Wegovy because of hair loss?

You and your prescriber should make that call together, but the evidence argues against stopping by reflex. The STEP 4 withdrawal trial (the label's Study 5) shows what happens to the weight: after a 20-week run-in to 2.4 mg, people switched to placebo regained 6.9% of their body weight over the next 48 weeks, while those who stayed on Wegovy lost another 7.9%[5][1]. Stopping does not pull hairs already in the resting phase back into growth, and a 2026 meta-analysis of GLP-1 alopecia specifically advised clinicians to avoid premature discontinuation, focusing on nutrition and counseling instead[11].

The label does offer room to adjust: the weight-management maintenance dose can be 1.7 mg rather than 2.4 mg, and moving to 7.2 mg is optional[1]. In the 7.2 mg trials, five people had their dose reduced because of hair loss[1]. If shedding is distressing, asking whether to hold at your current dose rather than stepping up is a reasonable conversation to have.

The mechanism, briefly

At any moment about 85% of scalp hairs are growing (anagen) and about 15% are resting (telogen). A significant metabolic stress can push a large share of growing hairs into the resting phase at once; they fall out together weeks later. Crash dieting, low protein intake and iron deficiency are all listed triggers[8]. The hair loss is nonscarring, so the follicles stay intact.

For Wegovy, the GLP-1 review authors suggest the driver may be the calorie restriction itself — too little energy and protein reaching the hair matrix — rather than the weight change alone[10]. That points to something you can influence: how much you eat while your appetite is suppressed. The review found no strong evidence that GLP-1 drugs permanently damage hair follicles[10].

What helps while you stay on Wegovy

  • Don't let appetite suppression become a crash diet. Prevention strategies in the GLP-1 hair-loss literature start with avoiding dramatic weight loss and severe calorie restriction[10]. If you're eating far less than you did before Wegovy, that's worth raising with your prescriber or a dietitian.
  • Prioritize protein and key micronutrients. The same review lists adequate protein, iron, zinc, vitamin D, B12 and vitamin A[10]. Our GLP-1 protein calculator turns your weight into a daily gram target.
  • Ask about basic labs if shedding persists. A complete blood count, ferritin, TSH and vitamin D are the suggested starting panel, especially after rapid loss or very low intake[10]. Don't start high-dose iron without a test.
  • Check the pattern. Diffuse shedding all over the scalp, hairs that come out easily on a gentle pull, and no patterned thinning point to telogen effluvium; patterned thinning points to androgenetic (pattern) hair loss, which has its own treatments such as topical minoxidil[10]. Our review of finasteride and minoxidil on GLP-1s covers that evidence.
  • Track your week. The GLP-1 side-effect timeline shows where hair loss usually falls relative to other Wegovy side effects.

When to see a clinician

  • Round, patchy bald spots. That suggests alopecia areata, a separate autoimmune condition; the 2026 meta-analysis did not find a significant link between GLP-1 drugs and alopecia areata[11], so don't assume Wegovy is the cause.
  • Red, painful, shiny or smooth patches. Telogen effluvium is nonscarring[8]; scarring hair loss needs a dermatologist promptly.
  • Patterned thinning rather than diffuse shedding — more consistent with androgenetic alopecia, which the 2026 meta-analysis did associate with GLP-1 use[11].
  • Shedding that keeps going after your weight has leveled off — a reason for the lab panel above[10].

How Wegovy compares with the other brands: Zepbound and Mounjaro (tirzepatide) each have their own label figures, and the GLP-1 hair loss overview puts every label side by side. Prescribing details for the drug itself are on the Wegovy drug page.

Our reviews

Providers that offer semaglutide

Telehealth providers we’ve reviewed. Each opens our full, independent review.

We may earn a commission from featured partners. Learn more

See the full ranking →

Frequently Asked Questions

Yes, in a minority of people. The Wegovy prescribing information lists hair loss as a common side effect: 3.3% of adults on 2.4 mg vs 1% on placebo in the 68-week trials, rising to 5.8% on 7.2 mg. The label says the hair loss was associated with weight reduction.
Much more common than for men. On Wegovy 2.4 mg, 4% of women reported hair loss (vs 2% of women on placebo) compared with 0.9% of men. In the 7.2 mg trials, 8.4% of women on 7.2 mg reported it vs 0.2% of men.
Weight-loss shedding usually lags its trigger by about 1.5–3 months, so on Wegovy it often appears late in the 16-week dose escalation or soon after reaching the maintenance dose. A later dose increase, such as 2.4 mg to 7.2 mg, can be followed by a new shedding window.
For telogen effluvium, the pattern most GLP-1 hair loss resembles, the follicles are not scarred and shedding typically improves within 3–6 months after weight stabilizes. Patchy, scarring or patterned hair loss is different and should be checked by a clinician.
The label does not give a separate hair-loss rate for the 25 mg Wegovy tablet. It says the types and frequency of common side effects in the tablet trial were similar to those in the injection trials, where hair loss was 3% vs 1% on placebo.
Talk to your prescriber first. Stopping does not reverse hair already shedding, and in the STEP 4 trial people switched to placebo regained 6.9% of body weight. Options include eating enough protein, checking labs if shedding persists, and discussing whether to hold your current dose instead of increasing it.

References

  1. 1.Novo Nordisk Inc. WEGOVY (semaglutide) injection and tablets — US Prescribing Information, Sections 2 (Dosage), 6.1 (Clinical Trials Experience: Hair Loss) and 14 (Clinical Studies). DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. 2.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID: 33567185.
  3. 3.Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. PMID: 33667417.
  4. 4.Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021. PMID: 33625476.
  5. 5.Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID: 33755728.
  6. 6.Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, Quiroga M, Rosenstock J, Garvey WT; STEP UP trial group. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025. PMID: 40961952.
  7. 7.Weghuber D, Barrett T, Barrientos-Pérez M, Gies I, Hesse D, Jeppesen OK, Kelly AS, Mastrandrea LD, Sørrig R, Arslanian S; STEP TEENS Investigators. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022. PMID: 36322838.
  8. 8.Hughes EC, Syed HA, Saleh D. Telogen Effluvium. StatPearls Publishing. 2024. PMID: 28613598.
  9. 9.Kang DH, Kwon SH, Sim WY, Lew BL. Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 2024. PMID: 39623615.
  10. 10.Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Sci Prog. 2026. PMID: 41998799.
  11. 11.Viquez Burboa GU, Flores Guillén MÁR, Duardo González VS. GLP-1 Receptor Agonists and Alopecia: A Systematic Review and Meta-Analysis of Incidence, Risk, Subtypes, and Mechanisms. Skin Appendage Disord. 2026. PMID: 42621629.

Where to get semaglutide (Ozempic / Wegovy) safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.3

CoreAge Rx

Lowest-price compounded semaglutide and tirzepatide with one flat price at every dose

Read full review →

From $79/mo

starting price

Get started →
7.8

Embody

Low flat-rate compounded GLP-1 pricing at every dose

Read full review →

From $79/mo

sale price

Get started →
8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $129/mo

starting dose

Get started →

About this analysis

Weight Loss Rankings is an independent editorial publication. Our provider dataset is verified directly against each provider's website and updated continuously. Read our full methodology →